The price you pay for Gilenya may depend on factors such as your dosage, whether you have health insurance, and the pharmacy you use. Financial assistance may be available to help you with the ...

Gilenya made revenues of $2.8 billion in 20021, with half of that total coming from the US market, although it has started to shrink as a result of increased competition in the market for ...

Novartis has released new data showing that its drug Gilenya benefited patients by improving all four key measures of multiple sclerosis (MS). Gilenya (fingolimod) is the first once-daily oral ...

A U.S. court of appeals has reportedly ruled that a whistleblower case against Novartis (NYSE:NVS) over alleged kickbacks involving its multiple sclerosis drug Gilenya can proceed. The Second U.S ...

Earnings reflect R&D investments in 2024 including the acquisition of Kate Therapeutics, Mariana Oncology, IFM Due, MorphoSys AG, Calypso Biotech BV, and SanReno Therapeutics. Additionally, as the ...

While patent losses on multiple sclerosis drug Gilenya and cancer drug Afinitor will weigh on near-term growth, a strong portfolio of drugs along with a robust pipeline should ensure a steady long ...